Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 132236 | Registry Identifier | JAPIC-CTI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with dyslipidemia when added to an existing statin-modifying therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anacetrapib | Experimental | Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension. |
|
| Placebo | Placebo Comparator | Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anacetrapib | Drug |
|
| |
| Placebo for anacetrapib |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change from Baseline in LDL-C (beta-quantification [BQ] method) | Baseline and Week 24 | |
| Percentage of Participants who Experience at Least One Adverse Event (AE) | 64 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C) | Baseline and Week 24 | |
| Percent Change from Baseline in Non-HDL-C | Baseline and Week 24 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28478132 | Result | Teramoto T, Daida H, Ikewaki K, Arai H, Maeda Y, Nakagomi M, Shirakawa M, Watanabe Y, Kakikawa T, Numaguchi H, Johnson-Levonas AO, Blaustein RO. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis. 2017 Jun;261:69-77. doi: 10.1016/j.atherosclerosis.2017.03.009. Epub 2017 Mar 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Percent Change from Baseline in Apolipoprotein B (Apo-B) |
| Baseline and Week 24 |
| Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I) | Baseline and Week 24 |
| Percent Change from Baseline in Lipoprotein(a) (Lp[a]) | Baseline and Week 24 |
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C530884 | anacetrapib |
Not provided
Not provided
Not provided